Related Experiment Video

Updated: Mar 24, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.6K

New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members

Yaowu He1, Brittney S Harrington1, John D Hooper1

  • 1Cancer Biology and Management Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, Australia.

Oncoscience
|March 15, 2016
PubMed

Insights

The receptor CDCP1 promotes cancer and therapy resistance. Targeting CDCP1 with agents like antibodies shows promise for treating specific cancers, especially when CDCP1 signaling partners are activated.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The CUB domain-containing protein 1 (CDCP1) receptor is implicated in cancer progression.
  • CDCP1 signaling pathways are involved in chemo- and targeted-therapy resistance.
  • Elevated CDCP1 expression correlates with poorer patient outcomes in several malignancies.

Purpose of the Study:

  • To summarize the role of CDCP1 in cancer.
  • To review evidence for CDCP1 as a therapeutic target.
  • To highlight potential treatment strategies for CDCP1-driven cancers.

Main Methods:

  • Review of existing literature on CDCP1 signaling in cancer.
  • Analysis of preclinical data on CDCP1-targeted agents.
  • Correlation of CDCP1 expression with clinical outcomes.

Main Results:

  • CDCP1 signaling pathways are crucial for cancer promotion.
  • CDCP1 activation is linked to resistance against cancer treatments.
  • Preclinical studies indicate efficacy of CDCP1-targeted therapies.

Conclusions:

  • CDCP1 is a significant factor in cancer development and treatment resistance.
  • Therapeutic antibodies targeting CDCP1 represent a promising approach.
  • Patient selection based on CDCP1 and its signaling partners (EGFR, HER2, Met, Src) is key for effective treatment.
Keywords:
CDCP1EGFRHER2MetSrcantibody

More Related Videos

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.7K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K